





Certificate delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020

The project proposal 829797, ADRISK

ApoE4 Blood Marker Assay. A New Non-Genetic Method to Evaluate Alzheimer's Disease Risk Using Clinical Chemistry Analyzers

Submitted under the Horizon 2020's SME instrument phase 2 call H2020-EIC-SMEInst-2018-2020 (H2020-SMEInst-2018-2020-2) of 23 May 2018 in the area of EIC-SMEInst-2018-2020

SME instrument

by

BIOCROSS S.L.

FRANCISCO VALLÉS 8, 47151 VALLADOLID Spain

following evaluation by an international panel of independent experts

WAS SCORED AS A HIGH-QUALITY PROJECT PROPOSAL IN A HIGHLY COMPETITIVE EVALUATION PROCESS*

This proposal is recommended for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

* This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria (excellence, impact, quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020.

Corina Cretu,

Commissioner for Regional Policy


rete

Carlos Moedas

Commissioner for Research Science and Innovation

Cer?

Brussels, 28/06/2018



This document is digitally sealed. The digital sealing mechanism uniquely binds the document to the modules of the Participant Portal of the European Commission, to the transaction for which it was generated and ensures its integrity and authenticity.

Any attempt to modify the content will lead to a breach of the electronic seal, which can be verified at any time by clicking on the digital seal validation symbol.